Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Timothy P. Hughes(South Australia Pathology), Susan Branford(Centre for Cancer Biology), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Naranie Shanmuganathan(South Australia Pathology), David M. Ross(South Australia Pathology), Jodi Braley(South Australia Pathology), Anthony K. Mills(Princess Alexandra Hospital), Chung Hoow Kok(South Australian Health and Medical Research Institute), John F. Seymour(The Royal Melbourne Hospital), Verity A Saunders(South Australia Pathology), Ilaria S. Pagani(South Australian Health and Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Andrew Grigg(The Royal Melbourne Hospital), Anthony P. Schwarer(The Alfred Hospital), Robin Filshie(St Vincent's Hospital Melbourne), David T Yeung(South Australia Pathology), Phuong Dang(South Australia Pathology)
Cited by 78
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k